Carboplatin is a platinum-based chemotherapy drug used in multiple cancers including ovarian, lung, head and neck, brain cancers, and neuroblastoma. It was developed as a less toxic analogue of cisplatin and is administered intravenously. It is prescription-only and has long-standing global clinical use.
Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.
Two studies report on thoracic radiotherapy for lung cancer: a phase III trial found adding radiotherapy to chemoimmunotherapy did not improve survival in extensive-stage small cell lung cancer, while a retrospective review showed high local control rates with single-fraction 28 Gy stereotactic body radiotherapy.
Neoadjuvant chemoimmunotherapy showed a 51.5% pathological complete response rate in 127 patients with resectable squamous cell lung cancer. Grade 3-4 treatment-related adverse events occurred in 11.8% of patients.
The ASCENT-04 trial shows Trodelvy plus Keytruda extends progression-free survival by 3.4 months in PD-L1-positive metastatic triple-negative breast cancer. Meanwhile, the ToPCourT trial investigates trilaciclib combined with pembrolizumab and chemotherapy for advanced TNBC. These developments signal evolving treatment approaches for this aggressive breast cancer subtype.
Moderna and Merck advance a Phase 2 trial of mRNA cancer vaccine V940 with pembrolizumab and chemotherapy for metastatic squamous NSCLC. In biliary tract cancer, first-line treatment combines chemotherapy with immunotherapy, while targeted therapy resistance prompts liquid biopsy. ImmunityBio tests a chemotherapy-free NK-cell regimen in non-Hodgkin lymphoma.
Multiple phase 3 breast cancer trials reported significant findings in early 2026, including positive results for novel therapies across different subtypes. Key data includes progression-free survival benefits for palbociclib in HR-positive, HER2-positive advanced breast cancer and investigations of antibody-drug conjugates and combination therapies. Full trial findings are expected to be presented at upcoming medical meetings.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
New antibody-based approaches demonstrate clinical benefits across multiple cancer types, including improved survival in triple-negative breast cancer, enhanced tumor detection via PET imaging, and activity in relapsed mantle cell lymphoma.
New technologies combining patient-derived organoid models with artificial intelligence are enabling researchers to predict treatment responses and monitor tumor behavior in ways that could advance personalized cancer care.
New combination therapies demonstrate improved outcomes in advanced anal and colorectal cancers, with retifanlimab plus chemotherapy approved for anal cancer and onvansertib showing strong efficacy signals in RAS-mutated colorectal cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07612137 |
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07586202 |
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07583550 |
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07564141 |
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07559929 |
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07544654 |
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy |
NOT_YET_RECRUITING | PHASE3 |
| NCT07527806 |
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging |
NOT_YET_RECRUITING | PHASE2 |
| NCT07504588 |
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07502300 |
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07498907 |
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
